The number of people living with undiagnosed HIV is increasing in the WHO European Region. According to data published today by ECDC and the WHO/Europe, more than 136 000 people were newly diagnosed in 2019 – roughly 20% of these were diagnosed in the EU/EAA and 80% in the eastern part of the European Region. Every second HIV diagnosis (53%) happens at a late stage of the infection, when the immune system has already started to fail. This is a sign that testing strategies in the Region are not working properly to diagnose HIV early.
Depending on the level of evidence provided and the methodology used, this advice is typically conveyed through a Guidance, a Systematic review or an Expert opinion.
HIV combination prevention is an approach that brings together single prevention initiatives into a comprehensive programme. This approach considers that the offer of multiple evidence-based interventions in a comprehensive programme will have a greater impact on HIV transmission than investing in a single strategy. In this report we
present and test the feasibility of a novel approach to monitoring the implementation of combination HIV prevention at national level.
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.